AstraZeneca PLC Stock Forecast for 2022 - 2025 - 2030
Updated on 18.08.2022
AstraZeneca PLC has an average price target of £145,69 recently offered by thridteen notable experts for 2022, which would represent a potential upside of approximately 32,42% from the last closing price in August, 2022 if reached. This potential increase is based on a high estimate of £187,59 and a low estimate of £83,61. If you're looking to buy AstraZeneca PLC stock, you may also want to check out its rivals.
32,42% Upside
AstraZeneca PLC Fair Value Forecast for 2022 - 2025 - 2030
AstraZeneca PLC's Price has grown in the last three years, jumping from £59,51 to £90,99 – an increase of 52,89%. In the next year, analysts predict that Fair Value will reach £102,54 – an increase of 12,70%. For the next nine years, the forecast is for Fair Value to grow by 198,83%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
12
|
$167,58 | $186,00 | 10,40% | 15 |
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$316,82 | $281,95 | 8,89% | 12 |
| PFE Stock Forecast | Pfizer | Outperform |
3
|
$49,27 | $56,86 | 11,63% | 16 |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$141,44 | $164,23 | 13,12% | 19 |
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
18
|
kr773,00 | kr678,96 | 15,14% | 14 |
AstraZeneca PLC Revenue Forecast for 2022 - 2025 - 2030
AstraZeneca PLC's Revenue has grown in the last three years, jumping from £22,09B to £37,42B – an increase of 69,38%. In the next year, analysts predict that Revenue will reach £43,24B – an increase of 15,55%. For the next nine years, the forecast is for Revenue to grow by 235,44%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| MRK Stock Forecast | Merck | Outperform |
6
|
$91,04 | $91,73 | 9,84% | 19 |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
14
|
$110,55 | $128,88 | 13,98% | 19 |
| NOVN Stock Forecast | Novartis | Outperform |
18
|
CHF81,23 | CHF103,75 | 17,79% | 10 |
AstraZeneca PLC Dividend per Share Forecast for 2022 - 2025 - 2030
In the last three years, AstraZeneca PLC's Dividend per Share has increased by 2,50%, going from £2,80 to £2,87. In the next year, analysts are expecting an increase in Dividend per Share, predicting it will reach £2,89 – an increase of 0,81%. The AstraZeneca PLC forecast is for Dividend per Share to reach £3,18 or grow by 10,88%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Outperform |
2
|
$74,56 | $79,05 | 11,32% | 16 |
| AMGN Stock Forecast | Amgen | Hold |
9
|
$250,58 | $246,51 | 1,76% | 13 |
| MDT Stock Forecast | Medtronic | Outperform |
18
|
$94,91 | $109,62 | 14,85% | 5 |
AstraZeneca PLC Free Cash Flow Forecast for 2022 - 2025 - 2030
AstraZeneca PLC's Free Cash Flow has increased by 209,33% In the last three years, going from £1,58B to £4,87B. In the next year, analysts expect Free Cash Flow to reach £6,34B – an increase of 30,07%. For the next nine years, the forecast is for Free Cash Flow to grow by 449,31%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| CSL Stock Forecast | CSL | Outperform |
16
|
$292,50 | $228,01 | -23,62% | 6 |
| GILD Stock Forecast | Gilead Sciences | Outperform |
11
|
$66,02 | $69,65 | 6,03% | 19 |
| MRK Stock Forecast | MERCK Kommanditgesellschaft au... | Outperform |
18
|
182,90€ | 147,51€ | 12,08% | 15 |
AstraZeneca PLC Net Income Forecast for 2022 - 2025 - 2030
In the last three years, AstraZeneca PLC's Net Income has gone down from £2,16B to £112,00M – a 94,80% drop. For next year, the 0 analysts predict Net Income of £1,18B, which would mean an increase of 957,74%. Over the next nine years, the pros' prediction is Net Incomeof £1,89T, which would mean a nine-year growth forecast of 1690723,96%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$264,23 | $274,67 | 5,97% | 3 |
| GSK Stock Forecast | GSK | Outperform |
16
|
£14,15 | £16,08 | 37,10% | 15 |
| MRNA Stock Forecast | Moderna | Outperform |
11
|
$158,00 | $0,00 | 22,47% | 3 |
AstraZeneca PLC EBITDA Forecast for 2022 - 2025 - 2030
In the last three years, AstraZeneca PLC's EBITDA has grown, increasing from £4,49B to £8,37B – a growth of 86,32%. The next year looks promising for AstraZeneca PLC, with analysts predicting EBITDA of £9,94B – an increase of 18,72%. Over the next nine years, experts anticipate that AstraZeneca PLC's EBITDA will grow at a rate of 233,63%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
18
|
¥4,14k | ¥0,00 | 3,99% | 0 |
| BAYN Stock Forecast | Bayer | Outperform |
7
|
53,37€ | 67,79€ | 46,15% | 14 |
| 4519 Stock Forecast | Chugai Pharmaceutical | Hold |
18
|
¥3,88k | ¥0,00 | 16,01% | 0 |
AstraZeneca PLC EBIT Forecast for 2022 - 2025 - 2030
In the last three years, AstraZeneca PLC's EBIT has grown by 159,16%, from £1,76B to £4,57B. For the next year, analysts are expecting EBIT to reach £5,75B – an increase of 25,82%. Over the next nine years, experts predict that EBIT will grow by 259,37%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| LONN Stock Forecast | Lonza Group Ltd | Outperform |
16
|
CHF560,60 | CHF756,46 | 40,47% | 5 |
| BAS Stock Forecast | BASF | Outperform |
11
|
42,69€ | 78,27€ | 28,84% | 16 |
| BNTX Stock Forecast | BioNTech | Outperform |
12
|
$152,04 | $0,00 | 31,93% | 5 |
AstraZeneca PLC EPS Price Prediction Forecast for 2022 - 2025 - 2030
AstraZeneca PLC's EPS has grown in the last three years, jumping from £3,46 to £5,29 – an increase of 52,89%. In the next year, analysts predict that EPS will reach £5,96 – an increase of 12,70%. For the next nine years, the forecast is for EPS to grow by 198,83%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| ILMN Stock Forecast | Illumina | Outperform |
16
|
$213,02 | $258,53 | 13,13% | 11 |
| BIIB Stock Forecast | Biogen | Outperform |
11
|
$217,58 | $242,78 | 5,71% | 24 |
| BAX Stock Forecast | Baxter International | Outperform |
17
|
$61,38 | $69,92 | 12,41% | 3 |